The company’s rabies candidate, RBI-4000, was able to elicit an immune response comparable to Bavarian Nordic’s RavAvert.

A complex molecular machine, the spliceosome, ensures that the genetic information from the genome, after being transcribed ...

Replicate Bioscience, a clinical-stage company pioneering novel self-replicating RNA (srRNA) technology for applications across infectious disease, immunology, and other therapeutic areas, today ...

WVE-007 is a novel, long-acting GalNAc-siRNA targeting INHBE mRNA – a genetically validated target that provides a new approach for healthy, sustainable ...

(NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today ...